The ABRACL Knockout HeLa Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population of the HeLa cell line, with targeted disruption of the ABRACL gene. This heterogeneous pool contains cells carrying diverse edits that collectively abolish ABRACL protein expression, providing a reliable loss-of-function model for studying gene function in a population context. The polyclonal format minimizes artifacts from single-cell cloning and captures a broad range of phenotypes, enhancing reproducibility in downstream assays.
HeLa cells are an immortalized human cervical adenocarcinoma line originally isolated from Henrietta Lacks, and they are positive for human papillomavirus 18 (HPV18). The viral oncoproteins E6 and E7 degrade p53 and retinoblastoma protein, respectively, leading to unregulated cell cycle progression and a highly proliferative state. This cell line is a cornerstone in cancer biology, virology, and drug development research, offering robust growth characteristics and compatibility with a wide spectrum of molecular and cellular assays.
ABRACL (ABRA C-terminal like) is a poorly characterized homolog of the actin-bundling protein ABRA. It is predicted to bind actin and participate in the reorganization of the actin cytoskeleton, potentially influencing cell migration and adhesion. Signaling input may be derived from RhoA, a GTPase that governs stress fiber formation and actomyosin contractility, and cofilin, which severs actin filaments to regulate dynamics. ABRACL likely integrates these signals, modulating F-actin architecture and cellular motility.
When disrupted in HeLa cells, ABRACL loss offers a clear system to dissect actin-regulatory mechanisms underlying carcinoma cell migration and invasion. The HPV-transformed background primes these cells for enhanced motility, allowing researchers to directly correlate ABRACL deficiency with changes in wound healing, transwell migration, and proliferation. This knockout model is therefore instrumental for elucidating how ABRACL functions within oncogenic signaling networks.
Research applications include validation of ABRACL depletion via Western blotting and RT-qPCR, visualization of actin cytoskeleton changes by immunofluorescence, and functional assessment using wound healing and transwell migration assays. Protein?Cprotein interactions can be probed with co-immunoprecipitation, while transcriptional consequences are revealed by RNA-seq. The MTT assay enables quantification of proliferation effects. For additional technical details, please contact Ascent Research.
